Producer
Owen Mumford Ltd.
UK medical-device maker; Unifine pen needles and injection devices.
2
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
2 inputs Owen Mumford Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Owen Mumford Ltd. makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Pharmaceutical Services (device CDMO)
Diabetes & injection (branded)
Point-of-care & blood sampling
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Owen Mumford — a family-owned firm in Oxfordshire, England — invented the device that made home blood-glucose monitoring practical. Its Autolet, launched in the early 1980s, was the first automatic spring-loaded lancing device: a finger-pricker that delivered a consistent, near-painless skin puncture so people with diabetes could draw their own blood drop and test it at home rather than in a lab. Self-monitoring of blood glucose — the foundation of modern diabetes self-management used billions of times a year — traces directly to this small English company's spring-and-lancet mechanism. The same company now also makes the pen needles and autoinjectors for the GLP-1 drugs treating the metabolic diseases its lancet helped patients monitor.
Owen Mumford Ltd. ↗Concentration2024
The Western merchant autoinjector base is usually described as a Ypsomed–SHL duopoly, but Owen Mumford's Pharmaceutical Services arm is a genuine third independent player, supplying the Aidaptus autoinjector and UniSafe prefilled-syringe safety devices to pharma customers. It is smaller than the two leaders, yet its existence matters for resilience: in a GLP-1/biologics device-capacity crunch, the count of qualified non-captive autoinjector developers outside China is roughly three, not two. The thinness of that list — three European-anchored device CDMOs underpinning the world's injectable-drug delivery — is the real exposure.
Owen Mumford Ltd. ↗